US drugmakers' reliance on Chinese APIs poses supply chain risk

Analysts warn that US dependence on Chinese suppliers for common antibiotics and blood thinners leaves no reliable alternative if disrupted. The warning highlights a structural vulnerability in pharmaceutical supply chains, though no specific disruption has occurred. This matters for US healthcare security and potential policy responses.